(NASDAQ: EQ) Equillium's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.44%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.
Equillium's earnings in 2025 is -$20,194,000.On average, 6 Wall Street analysts forecast EQ's earnings for 2025 to be -$45,662,773, with the lowest EQ earnings forecast at -$61,228,816, and the highest EQ earnings forecast at -$27,490,489. On average, 6 Wall Street analysts forecast EQ's earnings for 2026 to be -$43,818,173, with the lowest EQ earnings forecast at -$65,893,869, and the highest EQ earnings forecast at -$18,743,515.
In 2027, EQ is forecast to generate -$19,612,262 in earnings, with the lowest earnings forecast at -$18,660,211 and the highest earnings forecast at -$19,993,083.